Resilience Establishes Multi-Product Development and Manufacturing Collaboration with Takeda’s Plasma-Derived Therapies Business Unit

SAN DIEGO, February 15, 2022–(BUSINESS WIRE)–National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines, today announced a manufacturing services agreement with Takeda’s Plasma-Derived Therapies Business Unit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220215005521/en/ Resilience’s 136,000 sq ft (12,800 m2) biomanufacturing facility in Mississauga provides process…

Read More